FIRVANQ KIT (Vancomycin Hydrochloride) Patent Expiration, LOE Window & CMS Spending

FIRVANQ KIT (Vancomycin Hydrochloride) by Azurity: FDA Orange Book core substance LOE 2035-03-13, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN208910 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-03-13
Last Listed Patent or Exclusivity Date2035-03-13
Orange Book Patents (*PED Extensions)20 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 23.5% 2-yr change)